Provided by Tiger Fintech (Singapore) Pte. Ltd.

Psyence Biomedical Ltd

0.6990
+0.00801.16%
Pre-market: 0.70030.0013+0.19%07:27 EDT
Volume:61.53K
Turnover:42.69K
Market Cap:3.16M
PE:0.00
High:0.7115
Open:0.6910
Low:0.6706
Close:0.6910
Loading ...

Psyence Biomedical Ltd - Nasdaq Grants Psyence Biomed Extension Until December 31, 2024

THOMSON REUTERS
·
20 Nov 2024

BRIEF-Psyence Biomedical Announces Effective Date For 1-For-75 Share Consolidation

Reuters
·
20 Nov 2024

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

THOMSON REUTERS
·
20 Nov 2024

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

GlobeNewswire
·
20 Nov 2024

Psyence Biomedical Announces Share Consolidation Strategy

TIPRANKS
·
13 Nov 2024

Psyence Biomedical Announces Results From Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination From Nasdaq

THOMSON REUTERS
·
13 Nov 2024

Press Release: Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Dow Jones
·
13 Nov 2024

GoodRx Holdings Faces Sell Rating Amid PBM Pressure and Business Model Challenges

TIPRANKS
·
08 Nov 2024

LTA to pilot blockchain-based conditional payments solution with OCBC

Nurdianah Md Nur
·
06 Nov 2024

Grab and Ant International use stablecoin payment system by StraitsX for cross-border merchant payment settlement

Nicole Lim
·
05 Nov 2024

Psyence Biomedical Acquires Stake in PsyLabs

TIPRANKS
·
02 Nov 2024

Decoding The Cigna Group (CI): A Strategic SWOT Insight

GuruFocus.com
·
01 Nov 2024

Psyence Group Closes Disposal of PsyLabs Stake; Shares Fall

MT Newswires Live
·
01 Nov 2024

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in Psylabs

THOMSON REUTERS
·
31 Oct 2024

Market Chatter: Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement

MT Newswires Live
·
30 Oct 2024

Psyence Group's Nasdaq-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase Iib Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

THOMSON REUTERS
·
25 Oct 2024